Physician profile
Ralph Taylor
NPI 1417005711
$11,195.06
in general payments reported to CMS, 2019-2025
37 companies · $923 in 2025
The $923 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,669 · 2020: $1,766 · 2021: $1,610 · 2022: $1,433 · 2023: $1,465 · 2024: $1,329 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,717.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,764.63 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,653.14 | 2019-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $710.95 | 2019-2022 | |
| Abbott Laboratories | $677.98 | 2019-2025 | Freestyle Libre 3, Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $663.60 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $591.81 | 2020-2024 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $538.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $434.70 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $430.38 | 2019-2022 | |
| Pfizer INC. | $407.57 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $400.33 | 2019-2022 | |
| Astellas Pharma US INC | $340.87 | 2019-2023 | Veozah |
| Esperion Therapeutics, INC. | $338.51 | 2021-2022 | |
| Abbvie INC. | $244.70 | 2021-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $235.74 | 2019-2024 | Repatha, Otezla |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.